Quantcast

Elsevier’s Maturitas Publishes Position Statement On Fertility Preservation

November 6, 2013

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of a position statement by the European Menopause and Andropause Society (EMAS) in the journal Maturitas on the topic of fertility preservation.

The rising need for fertility preservation results from two new 21st century changes. Improved survival of malignant disease with gonadotoxic treatments means that long-term reproductive potential should now be considered. Delaying childbirth means that the use of fertility preservation techniques to counter the normal age-related decline in fertility is also becoming a topic of interest for many healthy women.

This EMAS position paper provides and critically appraises evidence on available options for fertility preservation in both pre-pubertal and post-pubertal men and women. EMAS position paper recommends that all men and women of reproductive age should be thoroughly informed before the initiation of any gonadotoxic treatment about the possible risks of the treatment in question and all available options of fertility preservation should be discussed. Fertility preservation should be a priority when treating children or adults of reproductive age with agents that may have hazardous effects on the reproductive system and gonadotoxicity should be kept at a minimum.

These and other recommendations presented in the EMAS’ position statement on fertility preservation are published in the article: “EMAS Position statement: Fertility preservation,” published in Maturitas, Elsevier; available online on ScienceDirect.

On the Net:


Source: Elsevier



comments powered by Disqus